Who are Glatiramer Acetate (OL)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PF-06863135 + lenalidomide, injectable MS DMT, herbal immunomodulator, ferrous gluconate with lactoferrin, Glatiramer acetate (GA), β-1,3/1,6-D-glucan.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/glatiramer-acetate-ol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Glatiramer Acetate (OL) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Glatiramer Acetate (OL) (Glatiramer Acetate (OL)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunomodulator; disease-modifying therapy (DMT). Area: Immunology; Neurology.

phase 3 Immunomodulator; disease-modifying therapy (DMT) Myelin-reactive T cells; MHC class II molecules Immunology; Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Glatiramer Acetate (OL) (Glatiramer Acetate (OL)) — Teva Branded Pharmaceutical Products R&D, Inc.. Glatiramer acetate is a synthetic polypeptide that modulates immune responses by promoting anti-inflammatory T cell and B cell responses against myelin antigens.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Glatiramer Acetate (OL) TARGET	Glatiramer Acetate (OL)	Teva Branded Pharmaceutical Products R&D, Inc.	phase 3	Immunomodulator; disease-modifying therapy (DMT)	Myelin-reactive T cells; MHC class II molecules
PF-06863135 + lenalidomide	pf-06863135-lenalidomide	Pfizer	marketed	small molecule + immunomodulatory drug	unknown
injectable MS DMT	injectable MS DMT	Biogen	marketed	Immunomodulator (disease-modifying therapy)
herbal immunomodulator	herbal immunomodulator	Tatyasaheb Kore Dental College	marketed	Herbal immunomodulator
ferrous gluconate with lactoferrin	ferrous gluconate with lactoferrin	Ain Shams University	marketed	Iron supplement with immunomodulatory adjuvant
Glatiramer acetate (GA)	Glatiramer acetate (GA)	Teva Branded Pharmaceutical Products R&D, Inc.	marketed	Immunomodulator; disease-modifying therapy (DMT)
β-1,3/1,6-D-glucan	β-1,3/1,6-D-glucan	Al-Azhar University	marketed	Immunomodulator; biological response modifier	Dectin-1 (β-glucan receptor); Complement receptor 3 (CR3)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunomodulator; disease-modifying therapy (DMT) class)

Teva Branded Pharmaceutical Products R&D, Inc. · 2 drugs in this class
Federal University of São Paulo · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Glatiramer Acetate (OL) — Competitive Intelligence Brief. https://druglandscape.com/ci/glatiramer-acetate-ol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab